Collaboration revenue was $1M for the quarter ended December 31, 2022, and $1.9M for the year ended December 31, 2022. There was no collaboration revenue in the quarter or year ended December 31, 2021. Cash, cash equivalents and marketable securities were $554.8M as of December 31, 2022, compared with $360.4M as of December 31, 2021. Based on current operating plans, Verve expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into the second half of 2025.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VERV:
- Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
- Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
- Verve Therapeutics: VERVE-101 awarded Innovation Passport by UK MHRA
- Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
- 2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023
